The renin-angiotensin system blockade does not prevent renal interstitial fibrosis induced by aristolochic acids

Kidney International

Volumn 66, Issue 5, 2004, Pages 1815-1825

  Debelle, Frédéric D ^a   Nortier, Joëlle L ^b   Husson, Cécile P ^b   De Prez, Eric G ^b   Vienne, Anne R ^b   Rombaut, Katja ^b   Salmon, Isabelle J ^b   Deschodt Lanckman, Monique M ^b   Vanherweghem, Jean Louis ^b  

^a ERASME HOSPITAL   (Belgium)

^b NONE

Author keywords

Angiotensin type 1 receptor antagonist; Angiotensin converting enzyme inhibitor; Aristolochic acid; Chinese herb nephropathy; Rat model; Renal fibrosis; Renin angiotensin system

Indexed keywords

ANGIOTENSIN; ARISTOLOCHIC ACID; CANDESARTAN; ENALAPRIL; RENIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; TETRAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; ENZYME ACTIVITY; FIBROSING ALVEOLITIS; KIDNEY DISEASE; KIDNEY FUNCTION; MACROPHAGE; MALE; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; SODIUM INTAKE; ANIMAL; BLOOD PRESSURE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; DRUG POTENTIATION; FIBROSIS; KIDNEY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM RESTRICTION; WISTAR RAT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ARISTOLOCHIC ACIDS; BENZIMIDAZOLES; BLOOD PRESSURE; DIET, SODIUM-RESTRICTED; DRUG SYNERGISM; ENALAPRIL; FIBROSIS; KIDNEY; KIDNEY DISEASES; MALE; PEPTIDYL-DIPEPTIDASE A; RATS; RATS, WISTAR; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES;

EID: 21644463696     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.00905.x     Document Type: Article

References (51)

1. RISDON RA, SLOPER JC, DE WARDENER HE: Relationship between renal function and histological changes found in renal-biopsy specimens from patients with persistent glomerular nephritis. Lancet 2:363-366, 1968
2. SCHAINUCK LI, STRIKER GE, CUTLER RE, BENDITT EP: Structural-functional correlations in renal disease. II. The correlations. Hum Pathol 1:631-641, 1970
3. VANHERWEGHEM JL, DEPIERREUX M, TIELEMANS C, et al: Rapidly progressive interstitial renal fibrosis in young women: Association with slimming regimen including Chinese herbs. Lancet 341:387-391, 1993
4. DEPIERREUX M, VAN DAMME B, VANDEN HOUTE K, VANHERWEGHEM JL: Pathologic aspects of a newly described nephropathy related to the prolonged use of Chinese herbs. Am J Kidney Dis 24:172-180, 1994
5. VANHAELEN M, VANHAELEN-FASTRE R, BUT P, VANHERWEGHEM JL: Identification of aristolochic acid in Chinese herbs. Lancet 343:174, 1994
6. COSYNS JP, JADOUL M, SQUIFFLET JP, et al: Chinese herbs nephropathy: A clue to Balkan endemic nephropathy? Kidney Int 45:1680-1688, 1994
7. COSYNS JP, JADOUL M, SQUIFFLET JP, et al: Urothelial lesions in Chinese-herb nephropathy. Am J Kidney Dis 33:1011-1017, 1999
8. NORTIER JL, MARTINEZ MC, SCHMEISER HH, et al: Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 342:1686-1692, 2000
9. VANHERWEGHEM JL, DEBELLE FD, MUNIZ-MARTINEZ MC, NORTIER J: Aristolochic acid nephropathy after Chinese herbal remedies, in Clinical Nephrotoxins, 2nd ed, edited by De Broe ME, Porter GA, Bennett WM, Verpooten GA, Dordrecht, Kluwer Academic Publishers, 2003, pp 579-586
10. COSYNS JP, GOEBBELS RM, LIBERTON V, et al: Chinese herbs nephropathy-associated slimming regimen induces tumours in the forestomach but no interstitial nephropathy in rats. Arch Toxicol 72:738-743, 1998
11. DEBELLE FD, NORTIER JL, DE PREZ EG, et al: Aristolochic acids induce chronic renal failure with interstitial fibrosis in salt-depleted rats. J Am Soc Nephrol 13:431-436, 2002
12. YOUNG BA, BURDMANN EA, JOHNSON RJ, et al: Cyclosporine A induced arteriolopathy in a rat model of chronic cyclosporine nephropathy. Kidney Int 48:431-438, 1995
13. LEWIS EJ, HUNSICKER LG, BAIN RP, ROHDE RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329:1456-1462, 1993
14. RAVID M, SAVIN H, JUTRIN I, et al: Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 118:577-581, 1993
15. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 349:1857-1863, 1997
16. RUGGENENTI P, PERNA A, GHERARDI G, et al: Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 352:1252-1256, 1998
17. ANDERSEN S, TARNOW L, ROSSING P, et al: Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 57:601-606, 2000
18. LEWIS EJ, HUNSICKER LG, CLARKE WR, et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
19. CAMPBELL R, SANGALLI F, PERTICUCCI E, et al: Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int 63:1094-1103, 2003
20. LAFAYETTE RA, MAYER G, PARK SK, MEYER TW: Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest 90:766-771, 1992
21. ZATZ R, DUNN BR, MEYER TW, et al: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 77:1925-1930, 1986
22. KOHZUKI M, YASUJIMA M, KANAZAWA M, et al: Antihypertensive and renal-protective effects of losartan in streptozotocin diabetic rats. J Hypertens 13:97-103, 1995
23. IMAMURA A, MACKENZIE HS, LACY ER, et al: Effects of chronic treatment with angiotensin converting enzyme inhibitor or an angiotensin receptor antagonist in two-kidney, one-clip hypertensive rats. Kidney Int 47:1394-1402, 1995
24. KLAHR S, ISHIDOYA S, MORRISSEY J: Role of angiotensin II in the tubulointerstitial fibrosis of obstructive nephropathy. Am J Kidney Dis 26:141-146, 1995
25. DEBELLE F, NORTIER J, ARLT VM, et al: Effects of dexfenfluramine on aristolochic acid nephrotoxicity in a rat model for Chinese-herb nephropathy. Arch Toxicol 77:218-226, 2003
26. BRADFORD MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254, 1976
27. FRIEDLAND J, SILVERSTEIN E: A sensitive fluorimetric assay for serum angiotensin-converting enzyme. Am J Clin Pathol 66:416-424, 1976
28. MORRISSEY J, HRUSKA K, GUO G, et al: Bone morphogenetic protein-7 improves renal fibrosis and accelerates the return of renal function. J Am Soc Nephrol 13(Suppl 1):S14-S21, 2002
29. GUO G, MORRISSEY J, McCracken R, et al: Contributions of angiotensin II and tumor necrosis factor-alpha to the development of renal fibrosis. Am J Physiol Renal Physiol 280:F777-F785, 2001
30. INGERT C, GRIMA M, COQUARD C, et al: Effects of dietary salt changes on renal renin-angiotensin system in rats. Am J Physiol Renal Physiol 283:F995-1002, 2002
31. HARRIS RC, CHENG HF: The intrarenal renin-angiotensin system: A paracrine system for the local control of renal function separate from the systemic axis. Exp Nephrol 4(Suppl 1):2-7, 1996
32. OKAMURA A, RAKUGI H, OHISHI M, et al: Upregulation of renin-angiotensin system during differentiation of monocytes to macrophages. J Hypertens 17:537-545, 1999
33. RUIZ-ORTEGA M, LORENZO O, RUPEREZ M, EGIDO J: ACE inhibitors and AT(1) receptor antagonists-beyond the haemodynamic effect. Nephrol Dial Transplant 15:561-565, 2000
34. RUIZ-ORTEGA M, LORENZO O, SUZUKI Y, et al: Proinflammatory actions of angiotensins. Curr Opin Nephrol Hypertens 10:321-329, 2001
35. NORTIER JL, DESCHODT-LANCKMAN MM, SIMON S, et al: Proximal tubular injury in Chinese herbs nephropathy: Monitoring by neutral endopeptidase enzymuria. Kidney Int 51:288-293, 1997
36. COSYNS JP, DEHOUX JP, GUIOT Y, et al: Chronic aristolochic acid toxicity in rabbits: A model of Chinese herbs nephropathy? Kidney Int 59:2164-2173, 2001
37. LIU Y: Epithelial to mesenchymal transition in renal fibrogenesis: Pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 15:1-12, 2004
38. LAN HY: Tubular epithelial-myofibroblast transdifferentiation mechanisms in proximal tubule cells. Curr Opin Nephrol Hypertens 12:25-29, 2003
39. PETERS H, BORDER WA, NOBLE NA: Targeting TGF-beta overexpression in renal disease: Maximizing the antifibrotic action of angiotensin II blockade. Kidney Int 54:1570-1580, 1998
40. DIAMOND JR, ANDERSON S: Irreversible tubulointerstitial damage associated with chronic aminonucleoside nephrosis. Amelioration by angiotensin I converting enzyme inhibition. Am J Pathol 137:1323-1332, 1990
41. ZOJA C, CORNA D, CAMOZZI D, et al: How to fully protect the kidney in a severe model of progressive nephropathy: A multidrug approach. J Am Soc Nephrol 13:2898-2908, 2002
42. KATO S, LUYCKX VA, OTS M, et al: Renin-angiotensin blockade lowers MCP-1 expression in diabetic rats. Kidney Int 56:1037-1048, 1999
43. TAAL MW, CHERTOW GM, RENNKE HG, et al: Mechanisms underlying renoprotection during renin-angiotensin system blockade. Am J Physiol Renal Physiol 280:F343-F355, 2001
44. ISHIDOYA S, MORRISSEY J, MCCRACKEN R, KLAHR S: Delayed treatment with enalapril halts tubulointerstitial fibrosis in rats with obstructive nephropathy. Kidney Int 49:1110-1119, 1996
45. BURDMANN EA, ANDOH TF, NAST CC, et al: Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril. Am J Physiol 269:F491-F499, 1995
46. REMUZZI G, BERTANI T: Pathophysiology of progressive nephropathies. N Engl J Med 339:1448-1456, 1998
47. NATHAN CF: Secretory products of macrophages. J Clin Invest 79:319-326, 1987
48. NIKOLIC-PATERSON DJ, LAN HY, HILL PA, ATKINS RC: Macrophages in renal injury. Kidney Int 45(Suppl):S79-S82, 1994
49. ISHIDOYA S, MORRISSEY J, MCCRACKEN R, et al: Angiotensin II recepv tor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction. Kidney Int 47:1285-1294, 1995
50. WU LL, YANG N, ROE CJ, et al: Macrophage and myofibroblast proliferation in remnant kidney: Role of angiotensin II. Kidney Int 63(Suppl):S221-S225, 1997
51. RUIZ-ORTEGA M, BUSTOS C, HERNANDEZ-PRESA MA, et al: Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-kappa B activation and monocyte chemoattractant protein-1 synthesis. J Immunol 161:430-439, 1998